Overview
UPM Biomedicals is a leading producer of patented nanofibrillar cellulose technology derived from birch wood pulp for medical and life science applications. The company manufactures animal-free biomaterials under ISO 13485 quality management systems for 3D cell culture, drug discovery, tissue engineering, advanced wound care, implants, and personalized medicine. Their product portfolio includes FibGel, the world's first injectable nanocellulose hydrogel for permanent implantable medical devices, launched in October 2024.
Frequently asked questions
- What is UPM Biomedicals' core technology?
- UPM Biomedicals specializes in nanofibrillar cellulose (NFC) technology derived from birch wood pulp. This patented, animal-free biomaterial is biocompatible, sustainable, and tuneable for various medical and life science applications.
- What are the primary applications for UPM's products?
- Applications include 3D cell culture, drug discovery and screening, cell storage and transportation, 3D bioprinting, tissue engineering, advanced wound care, implants, personalized medicine, and novel drug formulations.
- What quality standards does UPM Biomedicals maintain?
- UPM Biomedicals manufactures clinical products under the ISO 13485 quality management system, ensuring compliance with medical device manufacturing standards.
- What is FibGel and when was it launched?
- FibGel is the world's first injectable nanocellulose hydrogel for permanent implantable medical devices, launched in October 2024. It is made from birch wood cellulose and water only, offering a safe, sustainable, and biocompatible alternative for medical device developers.
- Does UPM Biomedicals collaborate with other organizations?
- Yes, UPM Biomedicals has formed strategic collaborations, including a partnership with CELLINK for groundbreaking 3D bioprinting developments that combines UPM's nanocellulose biomaterials expertise with CELLINK's bioprinting methodology experience.